- Home
- KNSA vs VCYT Comparison
KNSA vs VCYT Comparison
Compare KNSA & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | VCYT |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | 824 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | KNSA | VCYT |
|---|---|---|
| Price | $43.66 | $36.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $52.33 | $46.00 |
| AVG Volume (30 Days) | 671.0K | ★ 817.1K |
| Earning Date | 02-24-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | 0.38 |
| Revenue | ★ $597,973,000.00 | $495,141,000.00 |
| Revenue This Year | $62.70 | $16.72 |
| Revenue Next Year | $31.18 | $11.31 |
| P/E Ratio | ★ $96.31 | $99.21 |
| Revenue Growth | ★ 55.68 | 16.41 |
| 52 Week Low | $18.12 | $22.61 |
| 52 Week High | $45.50 | $50.71 |
Technical Indicators
Market Signals| Indicator | KNSA | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 30.69 |
| Support Level | $42.99 | $40.29 |
| Resistance Level | $45.50 | $38.98 |
| Average True Range (ATR) | 1.69 | 1.79 |
| MACD | 0.28 | -0.54 |
| Stochastic Oscillator | 77.18 | 5.75 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.